Posted by Michael Wonder on 08 Sep 2019
ICER to assess treatments for ulcerative colitis
6 September 2019 - Report will be subject of CTAF meeting in June 2020; open Input now being accepted until 24 September 2019.
The Institute for Clinical and Economic Review (ICER) announced today that it plans to assess the comparative clinical effectiveness and value of therapies for ulcerative colitis (UC), including:
- Vedolizumab (Entyvio, Takeda), subcutaneous and IV formulations
- Infliximab (Remicade, Janssen)
- Infliximab-dyyb (Inflectra, Pfizer)
- Adalimumab (Humira, AbbVie)
- Golimumab (Simponi, Janssen)
- Tofacitinib (Xeljanz, Pfizer)
- Ustekinumab (Stelara, Janssen)
Takeda is seeking FDA approval for a subcutaneous version of vedolizumab, Janssen is currently pursuing an indication expansion for ustekinumab, and the FDA has already approved the other therapies for UC. The assessment will be publicly discussed during a meeting of the California Technology Assessment Forum in June of 2020, where the independent evidence review panel will deliberate and vote on evidence presented in ICER’s report.
